We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
-14.79%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$75.3M
AUM Growth
-$19.8M
Cap. Flow
-$2.07M
Cap. Flow %
-2.75%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICVX
1
DELISTED
Icosavax, Inc. Common Stock
ICVX
$27.2M 36.12%
3,510,228
– –
VTYX
2
DELISTED
Ventyx Biosciences
VTYX
$23.8M 31.65%
686,370
-60,000
-8% -$2.07M
TRML
3
DELISTED
Tourmaline Bio
TRML
$8.24M 10.94%
293,261
– –
HLVX
4
DELISTED
HilleVax
HLVX
$7.52M 9.98%
558,923
– –
JSPR icon
5
Jasper Therapeutics
JSPR
$22.4M
$5.96M 7.92%
851,965
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$1.57M 2.09%
2,370,142
– –
KZR
7
DELISTED
Kezar Life Sciences
KZR
$986K 1.31%
82,871
– –

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q3 2023 Portfolio in Review

As of Q3 2023, Qiming U.S. Ventures Management held 7 positions worth $75.3M, down 21% from $95.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 0%. Qiming U.S. Ventures Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management's biggest Q3 2023 reduction was Ventyx Biosciences, cutting an estimated $2.07M.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $75.3M portfolio in Q3 2023.
  • Qiming U.S. Ventures Management opened 0 new positions and closed 0 in Q3 2023.
  • Qiming U.S. Ventures Management's portfolio value fell 21% quarter-over-quarter to $75.3M.

Based on Qiming U.S. Ventures Management's 13F filing for Q3 2023, filed 9 Nov 2023.